Pyrimidyl cyclopentanes as AKT protein kinase inhibitors

A compound of the Formula:

• and enantiomers and salts thereof, wherein:
• G is phenyl, naphthalene, a 5-6 membered heteroaryl or a 9-10 membered bicyclic heteroaryl wherein the phenyl, naphthalene, 5-6 membered heteroaryl or 9-10 membered bicyclic heteroaryl is optionally substituted with one to four Ra groups;
• R1 and R1a are independently selected from H, Me, Et, —CH═CH2, —CH2OH, CF3, CHF2 or CH2F;
• R2 is H, —OH, —OMe or F;
• R2a is H, Me or F, or
• R2 and R2a are oxo;
• R3 is H, Me, Et, or CF3;
• R4 is H, 4-6 membered heterocycle, cyclopropylmethyl or C1-C4 alkyl optionally substituted with F, —OH or —O(C1-C3 alkyl);
• R5 and R5a are independently selected from H and C1-C4 alkyl, or R5 and R5a together with the atom to which they are attached form a carbonyl group, a 5-6 membered cycloalkyl or a 5-6 membered heterocycle, wherein the heterocycle has an oxygen heteroatom;
• each Ra is independently halogen, C1-C6-alkyl, C3-C6-cycloalkyl, —O—(C1-C6-alkyl), CF3, —OCF3, S(C1-C6-alkyl), CN, phenyl, —OCH2-phenyl, NH2, —NO2, —NH—(C1-C6-alkyl), —N—(C1-C6-alkyl)2, piperidine, pyrrolidine, pyrazole, pyridine, 2-aminopyrimidine, CH2F, CHF2, —OCH2F, —OCHF2, —OH, —SO2(C1-C6-alkyl), C(O)NH2, C(O)NH(C1-C6-alkyl), and C(O)N(C1-C6-alkyl)2;
• and
• j is 1 or 2;
• and when j is 2, the j ring carbon opposite NR4 may be replaced with an O heteroatom.